EHA: European Hematology Association

Conference Coverage

Acalabrutinib extends PFS in advanced CLL

AMSTERDAM – Monotherapy with the Bruton tyrosine kinase inhibitor acalabrutinib offered better progression-free survival, compared with rituximab-...

Conference Coverage

Ibrutinib tops chlorambucil against CLL

AMSTERDAM – The Bruton’s tyrosine kinase inhibitor was associated with a halving of risk for death, compared with chlorambucil.